Skip to content

Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial

Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02433041
Acronym
PRIDe
Enrollment
200
Registered
2015-05-04
Start date
2013-07-31
Completion date
2018-12-21
Last updated
2019-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium

Keywords

Postoperative delirium, Cortisol, NSE, S-100beta, MMSE, Nu-DESC, ICDSC, DOS, Haloperidol, Ketamine, Combination of Haloperidol and Ketamine, Placebo, Prevention of

Brief summary

The purpose of this study is to find out whether postoperative delirium can be more properly prevented by the combination of determined preventive agents in past studies. Further on the investigators measure pre- and postoperative cortisol, neuron specific enolase (NSE) and S-100beta levels.

Detailed description

The postoperative delirium remains a challenge for medical stuff concerning detection, therapy and avoidance of consequences. Over the years numerous risk factors were detected which emphasizes the importance of its prevention. Within these studies some possibilities, but no strictly defined rules of action for pharmacological or neuropsychological prevention are described. This is why in this randomized, double-blinded, placebo-controlled study, the investigators want to compare two agents that were found to prevent postoperative delirium to a certain level, even in combination: the investigators arrange the patients within four study groups, one receiving Haloperidol, one Ketamine, one both and one placebo. The patients receive the study drug only once right before induction of anesthesia. After the day of recruitment there is the day of operation and a follow-up of three days (5 days of observation in total, where the investigators will test cognitive function with Mini Mental Status Examination (MMSE), Delirium Observation Scale (DOS), Nursing Delirium Screening Scale (Nu-DESC) or Intensive Care Delirium Screening Checklist (ICDSC). Additionally the investigators will measure and compare pre- and postoperative Cortisol, NSE and S-100beta levels.

Interventions

DRUGHaloperidol

Haloperidol 0.005mg/kg at induction of anesthesia

DRUGKetamine

Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium

DRUGHaloperidol + Ketamine

Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together

Placebo being used in one of the four groups

Sponsors

Kantonsspital Baden
CollaboratorOTHER
University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 65 years and older * Signed agreement

Exclusion criteria

* Delirium at admittance or MMSE score \<24 points * High risk for postoperative ICU treatment * Haloperidol or Ketamine intolerance * Risk of lack of cooperation * Drug an alcohol abuse * Dementia * QT interval (QTc) prolongation (at least 460ms in men, at least 470ms women) or drugs influencing QT interval, such as class Ia and III antiarrhythmics, Gatifloxacin, Moxifloxacin, Pentamidin, Cotrimoxazol, Tacrolimus, Dolasetron * Parkinson's disease * Intake of dopaminergic drugs (Levodopa, dopamine agonists) * Parkinsonism * Epilepsy * Unable to be interviewed (severe Dementia, speaking disorders, intubation, respiratory isolation, aphasia, coma, terminal illness) * Delay of operation of more than 72 hours past hospital admittance * Body weight \>100kg

Design outcomes

Primary

MeasureTime frameDescription
Differences among study groups - Significant drop in MMSE of two points in one of the three postoperative follow-up days5 day follow-up (preoperative, day of surgery, postoperative days 1-3)Significant drop in MMSE of two points in one of the three postoperative follow-up days (ICU patients excluded)

Secondary

MeasureTime frameDescription
Quantification of incidence of postoperative delirium based on cognitive testing and lab parameters5 day follow-up (preoperative, day of surgery, postoperative days 1-3)Drop of one point in Nursing Delirium Screening Scale (Nu-DESC) compared pre- and postoperatively, comparison of levels of NSE, S-100beta and Cortisol (significantly elevated postoperatively?)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026